Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons

Neuroscience

Volumn 96, Issue 1, 2000, Pages 91-99

  Meshul, C K ^a   McGinty, J F ^b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Electron microscopy; Immunocytochemistry; Kappa opioid receptor; Nucleus accumbens; Opioid receptor; Striatum

Indexed keywords

DOPAMINE; GLUTAMIC ACID; KAPPA OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; ELECTRON MICROSCOPY; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE ENDING; NERVE FIBER; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; RAT; SYNAPSE VESICLE;

ANIMALS; AXONS; CAUDATE NUCLEUS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON; NUCLEUS ACCUMBENS; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA; SYNAPTIC VESICLES;

EID: 0033960493     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)90481-5     Document Type: Article

References (35)

1. Arvidsson U., Riedl M., Chakrabarti S., Vulchanova L., Lee J.-H., Nakano A.H., Lin X., Loh H.H., Law P.-Y., Wessendorf M.W., Elde R. The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc. natn. Acad. Sci. U.S.A. 92:1995;5062-5066.
2. Courtoy P.J., Picton D.H., Farquhar M.G. Resolution and limitations of the immunoperoxidase procedure in the localization of extracellular matrix antigens. J. Histochem. Cytochem. 31:1983;945-951.
3. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmac. exp. Ther. 244:1988;1067-1080.
4. Drake C.T., Chavkin C., Milner T.A. Kappa opioid receptor-like immunoreactivity is present in substance P-containing subcortical afferents in guinea pig dentate gyrus. Hippocampus. 7:1997;36-47.
5. Drake C.T., Patterson T.A., Simmons M.L., Chavkin C., Milner T.A. Kappa opioid receptor-like immunoreactivity in guinea pig brain: ultrastructural localization in presynaptic terminals in hippocampal formation. J. comp. Neurol. 370:1996;377-395.
6. Gannon R.L., Terrian D.M. U50488H inhibits dynorphin and glutamate release from guinea pig hippocampal mossy fiber terminals. Brain Res. 548:1991;242-247.
7. Glick S.D., Maisonneuve I.M., Raucci J., Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681:1995;147-152.
8. Gray A.M., Rawls S.M., Shippenberg T.S., McGinty J.F. The kappa opioid agonist, U-69593, decreases amphetamine-evoked behavior and dialysate levels of dopamine and glutamate in the nucleus accumbens of awake rats. J. Neurochem. 73:1999;1066-1074.
9. Heidbreder C.A., Goldberg S.R., Shippenberg T.S. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res. 616:1993;335-338.
10. Hill M.P., Brotchie J.M. Modulation of glutamate release by a κ-opioid receptor agonist in rodent and primate striatum. Eur. J. Pharmac. 281:1995;R1-R2.
11. Jiang Z.G., North R.A. Pre- and postsynaptic inhibition by opioids in rat striatum. J. Neurosci. 12:1992;356-361.
12. Kaddis F.G., Wallace L.J., Uretsky N.J. AMPA/kainate antagonists in the nucleus accumbens inhibit locomotor stimulatory response to cocaine and dopamine agonists. Pharmac. Biochem. Behav. 46:1993;703-708.
13. Karler R., Calder L.D., Turkanis S.A. Reverse tolerance to amphetamine evokes reverse tolerance to 5-hydroxytryptophan. Life Sci. 46:1991;1773-1780.
14. Kuzmin A.V., Semenova S., Gerrits M.A.F.M., Zvartau E.E., Van Ree J.M. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur. J. Pharmac. 321:1997;265-271.
15. Maisonneuve I.M., Archer S., Glick S.D. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181:1994;57-60.
16. Maneuf Y.P., Mitchell I.J., Crossman A.R., Woodruff G.N., Brotchie J.M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
17. 1 receptor in the rat CNS and pituitary. Neuroscience. 71:1996;671-690.
18. Meng F., Xie G.-X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. natn. Acad. Sci. U.S.A. 90:1993;9954-9958.
19. Meshul C.M., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following 6-hydroxydopamine lesion. Neuroscience. 88:1999;1-16.
20. Minami M., Hosoi Y., Toya T., Katao Y., Maekawa K., Katsumata S., Yabuuchi K., Onogi T., Satoh M. In situ hybridization study of kappa-opioid receptor mRNA in the rat brain. Neurosci. Lett. 162:1993;161-164.
21. Mulder A.H., Wardeh G., Hogenboom F., Frankhuyzen A.L. κ- and δ-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature. 308:1984;278-280.
22. 3H U69,593 binding sites in rat brain: evidence for kappa opioid receptor subtypes. Eur. J. Pharmac. 154:1988;27-34.
23. Novikoff A.B. DAB cytochemistry: artifact problems in its current use. J. Histochem. Cytochem. 28:1980;1036-1038.
24. Paxinos G. and Watson C. (1986) The Rat Brain in Sterotaxic Coordinates. Academic, Sydney.
25. Pierce R.C., Bell K., Duffy P., Kalivas P.W. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J. Neurosci. 16:1996;1550-1560.
26. Rawls S.M., McGinty J.F. κ Receptor activation attenuates L-trans-pyrrolidine-2,4-dicarboxylic acid-evoked glutamate levels in the striatum. J. Neurochem. 70:1998;626-634.
27. Rawls S.M., McGinty J.F., Terrian D.M. Presynaptic kappa opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes. J. Neurochem. 73:1999;1058-1065.
28. Reisine T., Bell G.I. Molecular biology of opiate receptors. Trends Neurosci. 16:1993;506-510.
29. Shuster S., Reid M., Li X., Vulchanova L., Elde R. Stimulus-dependent translocation of kappa opioid receptors to the plasma membrane. J. Neurosci. 19:1999;2658-2664.
30. Simmons M.L., Chavkin C. Kappa opioid receptor activation of a dendrotoxin-sensitive potassium channel mediates presynaptic inhibition of mossy fiber neurotransmitter release. Molec. Pharmac. 50:1996;80-85.
31. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. natn. Acad. Sci. U.S.A. 89:1992;2046-2050.
32. 5-enkephalin. J. Neurosci. 18:1998;1923-1933.
33. Svingos A.L., Colagio E.E.O., Pickel V.M. Cellular sites for dynorphin activation of κ-opioid receptors in the rat nucleus accumbens shell. J. Neurosci. 19:1999;1804-1813.
34. Unterwald E.M., Knapp C., Zukin R.S. Neuroanatomical localization of κ1 and κ2 opioid receptors in rat and guinea pig brain. Brain Res. 562:1991;57-65.
35. Wolf M.E., Jeziorski M. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization. Brain Res. 613:1993;291-294.